Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India's Expert Group Says Denying Patents To Incremental Innovations Will Not Be TRIPS-Compliant; Evergreening To Be Scrupulously Prevented

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Putting to rest wide speculation about applicability of the controversial Section 3 (d) of the Indian Patents Act, which deals with the treatment of incremental innovations, the Mashelkar Committee report - set up to dwell on Indian patent law issues - has recommended that incremental innovations should be encouraged

You may also be interested in...



Novartis Suffers Setback As Indian Patent Appeals Board Strikes Down Glivec Patent

MUMBAI - Hopes for Novartis to obtain a product patent for its chronic myeloid leukemia drug Gleevec (imatinib) were dashed after India's Intellectual Property Appellate Board ruled that Novartis' patent application covering the medicine's beta-crystalline version is not patentable because it failed to satisfy the requirements under Section 3(d) of the India Patents Act

Insider Analysis From Nishith Desai Associates: Learning And Unlearning From Section 3(d) Of The Indian Patents Act (Part 2 of 2)

By Milind Antani and Gowree Gokhale, Nishith Desai Associates, Mumbai, Indi

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

SC072541

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel